Why Oncologists Are Prescribing GLP-1s
Why Oncologists Are Prescribing GLP-1s

Why Oncologists Are Prescribing GLP-1s

When cancer specialists embrace – and when they avoid – this revolutionary drug class.

Given the increasing prevalence of weight-related conditions and the rapid uptake of GLP-1s on the one hand, and the increasing incidence of cancer on the other hand, it was inevitable that these two worlds would collide. In this paper, we uncover what's really happening at the intersection of two of healthcare's most defining challenges.

Improved patient outcomes, reduced treatment toxicity, enhanced drug efficacy – oncologists are finding compelling reasons to reach for GLP-1s. But concerns around drug interactions and unclear long-term effects reveal a more complex picture.

This essential read provides evidence-based understanding of why cancer specialists are embracing – and sometimes avoiding – this rapidly expanding drug class, and what clarity the industry needs to provide.

Why Oncologists Are Prescribing GLP-1s

Why Oncologists Are Prescribing GLP-1s

Explore the Findings

The author(s)

  • Pieter De Richter
    Pieter De Richter
    Regional Service Line Leader, Healthcare in APAC, Malaysia

More insights about Health

Related news